Compare Incyte Corporation (INCY) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marathon Petroleum Corp — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Marathon Petroleum Corp trades at $319.23 (market cap $92.05B). The key difference: Marathon Petroleum Corp is far larger — about 4× Incyte Corporation's market cap, and Marathon Petroleum Corp pays a 1.24% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MPC | |
|---|---|---|
Market Cap | $23.11B | $92.05B |
Sector | Health | Energy |
52-Week High | $118.52 | $315.31 |
52-Week Low | $67.38 | $158.59 |
Enterprise Value | $19.13B | $124.23B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Marathon Petroleum (MPC) trades at $319.76, up 2.29% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a 27.92% ROE and 3.42% net margin, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, while analyst consensus remains strongly bullish with 25 buy ratings and a $292.70 price target. The company benefits from strong refining margins and strategic upgrades driving profitability.
MPC presents a compelling investment case with strong profitability metrics and positive analyst sentiment, though investors should monitor declining revenue trends and elevated debt levels. The stock's current price near resistance levels suggests potential for consolidation, while refining margin advantages and limited Russian capacity create tailwinds. Key risks include oil price volatility and macroeconomic pressures on energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
